【財華社訊】君聖泰醫藥-B(02511.HK)公佈，公司自主研發的腸肝抗炎及代謝調節劑HTD1801(熊去氧膽小檗堿)針對2型糖尿病(T2DM)患者的2項III期臨床註冊試驗已完成患者入組。在該兩項試驗中，將評估HTD1801對T2DM患者糖化血紅蛋白及葡萄糖代謝、血脂、肝損傷/炎症標誌物及炎症等指標的作用。
君聖泰醫藥-B(02511.HK)完成HTD1801治療2型糖尿病III期臨床試驗患者入組
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.